220
Participants
Start Date
September 5, 2017
Primary Completion Date
December 31, 2022
Study Completion Date
June 30, 2026
Palbociclib
Palbociclib is a drug that may stop cancer cells from growing
Fulvestrant
Fulvestrant prevents growth of hormone receptor positive breast cancer by blocking stimulation of cancer cells by estrogen
Avelumab
Avelumab is an antibody designed to block the PD-1 pathway and helps the immune system in detecting and fighting cancer cells
University of Pennsylvania, Philadelphia
University of North Carolina at Chapel Hill, Chapel Hill
Emory University - Winship Cancer Institute, Atlanta
University of Miami, Miami
Vanderbilt University Medical Center, Nashville
University of Louisville, Louisville
Indiana University, Indianapolis
Aurora Cancer Care, Milwaukee
Northwestern University, Chicago
Washington University, St Louis
The University of Kansas Cancer Center - Lee's Summit, Lee's Summit
The University of Kansas Cancer Center - North, Kansas City
The University of Kansas Cancer Center, Westwood
The University of Kansas Cancer Center - Overland Park, Overland Park
Baylor University, Houston
Eastern Maine Medical Center, Bangor
Boston Medical Center, Boston
Dana-Farber Cancer Institute, Boston
Dana-Farber at St. Elizabeth's Medical Center, Brighton
DF/BWCC at Milford Regional Medical Center, Milford
DF/BWCC in clinical affiliation with South Shore Hospital, South Weymouth
Dana-Farber/New Hampshire Oncology-Hematology, Londonderry
Collaborators (1)
Pfizer
INDUSTRY
Dana-Farber Cancer Institute
OTHER